[go: up one dir, main page]

DK3043785T3 - Anvendelse af r-ketamin og salt deraf som lægemidler - Google Patents

Anvendelse af r-ketamin og salt deraf som lægemidler Download PDF

Info

Publication number
DK3043785T3
DK3043785T3 DK14793319.6T DK14793319T DK3043785T3 DK 3043785 T3 DK3043785 T3 DK 3043785T3 DK 14793319 T DK14793319 T DK 14793319T DK 3043785 T3 DK3043785 T3 DK 3043785T3
Authority
DK
Denmark
Prior art keywords
ketamin
medicines
salts
Prior art date
Application number
DK14793319.6T
Other languages
English (en)
Inventor
Kenji Hashimoto
Original Assignee
Univ Chiba Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chiba Nat Univ Corp filed Critical Univ Chiba Nat Univ Corp
Application granted granted Critical
Publication of DK3043785T3 publication Critical patent/DK3043785T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK14793319.6T 2013-09-13 2014-09-12 Anvendelse af r-ketamin og salt deraf som lægemidler DK3043785T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013190066 2013-09-13
PCT/JP2014/004730 WO2015037248A1 (en) 2013-09-13 2014-09-12 Application of r-ketamine and salt thereof as pharmaceuticals

Publications (1)

Publication Number Publication Date
DK3043785T3 true DK3043785T3 (da) 2021-11-15

Family

ID=51846870

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14793319.6T DK3043785T3 (da) 2013-09-13 2014-09-12 Anvendelse af r-ketamin og salt deraf som lægemidler

Country Status (16)

Country Link
US (5) US9872841B2 (da)
EP (2) EP3964203A1 (da)
JP (7) JP6366439B2 (da)
CA (2) CA2923685C (da)
CY (1) CY1125290T1 (da)
DK (1) DK3043785T3 (da)
ES (1) ES2897453T3 (da)
HR (1) HRP20211629T1 (da)
HU (1) HUE056378T2 (da)
LT (1) LT3043785T (da)
PL (1) PL3043785T3 (da)
PT (1) PT3043785T (da)
RS (1) RS62516B1 (da)
SI (1) SI3043785T1 (da)
SM (1) SMT202100641T1 (da)
WO (1) WO2015037248A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201802104QA (en) 2013-03-15 2018-05-30 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
DK3043785T3 (da) * 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
EP3297620A4 (en) 2015-06-27 2019-01-09 Shenox Pharmaceuticals, LLC TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
US11110070B2 (en) 2015-11-17 2021-09-07 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2018079693A1 (ja) 2016-10-27 2018-05-03 国立大学法人 千葉大学 (s)-ノルケタミンおよびその塩の医薬品としての応用
JP2021003001A (ja) * 2017-09-07 2021-01-14 国立大学法人千葉大学 うつ症状の検査方法、及び治療薬のスクリーニング方法
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
JP7265990B2 (ja) * 2017-09-27 2023-04-27 国立大学法人千葉大学 神経変性疾患あるいは認知機能障害の予防または治療剤としてのr-ケタミンおよびその誘導体
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
CN112423789A (zh) 2017-12-22 2021-02-26 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
CN118453559A (zh) * 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
US11426367B2 (en) * 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
JP7483630B2 (ja) * 2018-12-27 2024-05-15 国立大学法人千葉大学 神経発達障害の予防または治療剤としてのr-ケタミンおよびその誘導体
MX2021010683A (es) 2019-03-05 2021-12-10 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
WO2021026232A1 (en) * 2019-08-05 2021-02-11 The Ketamine Research Foundation Ketamine for the treatment of postpartum symptoms and disorders
CN112125816A (zh) * 2020-03-17 2020-12-25 国药集团工业有限公司 一种氯胺酮、其衍生物或其盐的消旋化方法
EP4125836A1 (en) 2020-03-27 2023-02-08 Homeostasis Therapeutics, Limited Method of treatment for anorexia nervosa, bulimia and related clinical syndromes
CN114306219B (zh) * 2020-09-30 2023-09-26 四川普锐特药业有限公司 稳定的r-氯胺酮药物组合物
JPWO2022118783A1 (da) * 2020-12-04 2022-06-09
CA3234818A1 (en) 2021-10-12 2023-04-20 Perception Neuroscience, Inc. R-ketamine salts and methods of use thereof
EP4493155A1 (en) 2022-03-14 2025-01-22 Perception Neuroscience, Inc. Pharmaceutical formulations of r-ketamine
CN115006375A (zh) * 2022-06-24 2022-09-06 华中科技大学 艾司氯胺酮用于制备治疗社交障碍药物的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254124A (en) 1962-06-29 1966-05-31 Parke Davis & Co Aminoketones and methods for their production
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
US4670459A (en) 1984-10-03 1987-06-02 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6382204B1 (en) 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
SI1257648T2 (sl) 2000-02-23 2016-11-30 Amgen Inc. Antagonistični selektivni vezavni agensi za osteoprotegerin vezavni protein
BRPI0002693B8 (pt) 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20040248964A1 (en) 2002-11-18 2004-12-09 Crooks Peter A. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
WO2007038949A1 (en) 2005-09-28 2007-04-12 Auris Medical Ag Pharmaceutical compositions for the treatment of inner ear disorders
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
CN104519878A (zh) 2012-03-12 2015-04-15 詹森药业有限公司 用于治疗顽固性或难治性抑郁症的艾氯胺酮
CN104902883A (zh) 2012-08-23 2015-09-09 斯图亚特·L·韦格 抗焦虑组合物、制剂及使用方法
SG10201802104QA (en) 2013-03-15 2018-05-30 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
KR20230156807A (ko) 2013-03-15 2023-11-14 얀센 파마슈티카 엔브이 S-케타민 하이드로클로라이드의 약제학적 조성물
KR102424765B1 (ko) 2013-04-12 2022-07-22 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
DK3043785T3 (da) * 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
EP3094312B1 (en) 2014-01-14 2019-03-13 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
EP3085366A1 (en) 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
US11110070B2 (en) 2015-11-17 2021-09-07 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
JP7265990B2 (ja) 2017-09-27 2023-04-27 国立大学法人千葉大学 神経変性疾患あるいは認知機能障害の予防または治療剤としてのr-ケタミンおよびその誘導体
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
JP7483630B2 (ja) 2018-12-27 2024-05-15 国立大学法人千葉大学 神経発達障害の予防または治療剤としてのr-ケタミンおよびその誘導体
WO2020232274A1 (en) 2019-05-15 2020-11-19 Bexson Biomedical, Inc. Ketamine formulation for subcutaneous injection

Also Published As

Publication number Publication date
CA2923685C (en) 2022-03-08
EP3043785A1 (en) 2016-07-20
EP3043785B1 (en) 2021-08-25
JP6366439B2 (ja) 2018-08-01
JP2015078181A (ja) 2015-04-23
EP3964203A1 (en) 2022-03-09
JP2024009274A (ja) 2024-01-19
JP7627514B2 (ja) 2025-02-06
US20240382436A1 (en) 2024-11-21
JP2021073310A (ja) 2021-05-13
JP6615277B2 (ja) 2019-12-04
HUE056378T2 (hu) 2022-02-28
US9872841B2 (en) 2018-01-23
JP2018145207A (ja) 2018-09-20
PT3043785T (pt) 2021-11-05
SMT202100641T1 (it) 2022-01-10
SI3043785T1 (sl) 2022-02-28
JP7398836B2 (ja) 2023-12-15
HRP20211629T1 (hr) 2022-02-04
US20190343781A1 (en) 2019-11-14
WO2015037248A1 (en) 2015-03-19
US20160220513A1 (en) 2016-08-04
US10406121B2 (en) 2019-09-10
JP2023011027A (ja) 2023-01-20
PL3043785T3 (pl) 2022-02-28
CA3143962A1 (en) 2015-03-19
RS62516B1 (sr) 2021-11-30
US11207279B2 (en) 2021-12-28
CA2923685A1 (en) 2015-03-19
US20220071929A1 (en) 2022-03-10
LT3043785T (lt) 2021-12-10
US20180177745A1 (en) 2018-06-28
CY1125290T1 (el) 2023-03-24
JP2025061458A (ja) 2025-04-10
ES2897453T3 (es) 2022-03-01
JP2020015766A (ja) 2020-01-30
JP6842206B2 (ja) 2021-03-17

Similar Documents

Publication Publication Date Title
DK3043785T3 (da) Anvendelse af r-ketamin og salt deraf som lægemidler
NO2021012I1 (no) avapritinib and pharmaceutically acceptable salts thereof
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
HUE057734T2 (hu) Heterociklusos vegyületek és alkalmazásuk
HUE046285T2 (hu) Omecamtiv mecarbil sói és eljárás a só elõállítására
DK2968208T3 (da) Behandling af kataplexi
DK2961388T3 (da) Kombinationer af lægemidler
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
DK4275756T3 (da) Bipyrazol-derivater som jak-hæmmere
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK3027618T3 (da) Polymorf af syk-hæmmere
HRP20180684T1 (hr) Kombinacija lijekova
HUE045209T2 (hu) Aramchol-sók
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3064491T3 (da) Sulfonamidderivat og medicinsk anvendelse deraf
DK3066089T3 (da) Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser
HUE043194T2 (hu) PLK-4 inhibitor sója és kristályformái
DK2968174T3 (da) Dobbelt anvendelige orale tabletter af farmaceutisk sammensætning af sulfatsalte og fremgangsmåder til anvendelse deraf
DK3041831T3 (da) Alfa-te-saltformer: sammensætninger og anvendelser til behandling af sygdom
DK3057963T3 (da) Piperazinderivater og anvendelse deraf som lægemidler
DK3598971T3 (da) Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin